Indoleamine-2,3-Dioxygenase 1 Enzyme Inhibition: a Useful Target to Screen Chemicals for their Therapeutic Potential
Gayatri Sawale1, Santosh Ghuge1, Sadhana Sathaye2
1Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Matunga, Mumbai, 400 019, India.
None:
Indoleamine 2,3-dioxygenase 1 (IDO1) is a key immunoregulatory enzyme that catalyzes the oxidative cleavage of L-tryptophan to N-formyl kynurenine, playing a critical role in immune tolerance and various pathological conditions, including cancer, autoimmune diseases, cataractogenesis, and neurodegenerative disorders. In this study, molecular docking was performed using a phytochemical library to identify compounds with strong binding affinity and favorable interactions within the IDO1 active site. Based on these in silico findings, selected compounds were further evaluated using a newly developed and cost-effective optimized fluorescence-based assay employing lens homogenate enzyme preparations to quantitatively assess IDO1 activity. Dose-response experiments revealed that several phytochemicals exhibited significant concentration-dependent inhibition of IDO1, with promising IC₅₀ values. The consistency between docking results and experimental inhibition supports the potential of these compounds as IDO1 inhibitors. This integrated in silico-in vitro approach provides a reliable platform for screening IDO1 modulators and identifies promising natural inhibitors for further development as therapeutics for IDO1-associated diseases.
More Related Videos
09:39Drug-induced Sensitization of Adenylyl Cyclase: Assay Streamlining and Miniaturization for Small Molecule and siRNA Screening Applications
Published on: January 27, 2014
08:31Anaerobic Protein Purification and Kinetic Analysis via Oxygen Electrode for Studying DesB Dioxygenase Activity and Inhibition
Published on: October 3, 2018
Related Concept Videos
Enzyme Inhibition
Drug Discovery: Overview
Drugs Affecting Neurotransmitter Synthesis
Experimental RNAi
Dipeptidyl Peptidase 4 Inhibitors
